Alterity Therapeutics (ATHE) Research & Development (2014 - 2025)

Alterity Therapeutics' Research & Development history runs 11 years deep, the most recent figure standing at -$9.5 million for Q4 2025.

• On a quarterly basis, Research & Development fell 39.81% year-over-year to -$9.5 million in Q4 2025; TTM through Dec 2025 was -$33.8 million, a 1.46% decrease from a year earlier, with the FY2025 full-year figure at $9.2 million, down 100.0% from the prior year.
• Research & Development eased to -$9.5 million in Q4 2025 per ATHE's latest filing, from -$6.8 million in the prior quarter.
• Across five years, Research & Development topped out at -$6.8 million in Q4 2024 and bottomed at -$9.5 million in Q4 2025.
• The 5-year median for Research & Development is -$9.0 million (2021), against an average of -$8.6 million.
• Across the five-year window, Research & Development advanced 18.23% in 2024 and slumped 39.81% in 2025, its largest moves.
• Year by year, Research & Development stood at -$9.0 million in 2021, then slipped by 2.99% to -$9.3 million in 2022, then climbed by 10.48% to -$8.3 million in 2023, then rose by 18.23% to -$6.8 million in 2024, then tumbled by 39.81% to -$9.5 million in 2025.
• Per Business Quant, the three latest ATHE Research & Development figures stand at -$9.5 million (Q4 2025), -$6.8 million (Q4 2024), and -$8.3 million (Q4 2023).